No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 984 | 893 | 986 | 1,115 | 1,258 | 1,300 | N/A | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | 187 | 177 | 295 | 251 | 393 | 262 | N/A | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relaxant, antitussive, antipruritic, scabicide, anti-inflammatory, antipyretic, analgesic, muscle relaxant, anxiolytic, antiemetic, anticonvulsant, anti-ulcerative, antihypertensive, a-blocker, vasodilator, bronchodilator, anxiolytic, tranquilizer, local anesthetic, decongestant, antispasmodic, neuroprotective, antimigraine, pharmaceutic aid/lubricant, antiglaucoma agent, hyponatremia, antidepressant, sedative, and analgesic, as well as treatment for hyperparathyroidism and urinary frequency, benign prostatic hypertrophy, and Herpes virus helicase-primase inhibitor. SYN-TECH Chem. & Pharm. Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
SYN-TECH Chem. & Pharm. Co., Ltd. (1777.TWO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relaxant, antitussive, antipruritic, scabicide, anti-inflammatory, antipyretic, analgesic, muscle relaxant, anxiolytic, antiemetic, anticonvulsant, anti-ulcerative, antihypertensive, a-blocker, vasodilator, bronchodilator, anxiolytic, tranquilizer, local anesthetic, decongestant, antispasmodic, neuroprotective, antimigraine, pharmaceutic aid/lubricant, antiglaucoma agent, hyponatremia, antidepressant, sedative, and analgesic, as well as treatment for hyperparathyroidism and urinary frequency, benign prostatic hypertrophy, and Herpes virus helicase-primase inhibitor. SYN-TECH Chem. & Pharm. Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.